E146: Did the Fed break the VC model? Plus IPOs, M&A, revaluing unicorns & more

This All-In Pod episode features a panel discussion covering major developments in venture capital, public markets, and the broader economy. The discussion opens with political analysis before pivoting to the All-In Summit 2023 recap and its key takeaways. The panel then addresses whether the Federal Reserve has fundamentally broken the venture capital model that thrived during the zero interest rate policy era. The conversation explores how LP evaluations of fund managers are shifting in response to higher rates and reduced fundraising activity. A major focus is the recent IPO activity, including Arm, Instacart, and Klaviyo going public, signaling potential reopening of capital markets. However, the panelists debate whether this represents a genuine recovery or merely a temporary thaw. The discussion of Instacart and Klaviyo's underlying business models reveals the quality of companies now accessing public markets and the metrics investors scrutinize most carefully. The panel addresses the significant challenge facing ZIRP-era unicorns like Airtable that raised capital at inflated valuations. These companies now must navigate substantial revaluations while adapting to investor expectations for profitability and efficient unit economics. The conversation examines what valuations these businesses might reasonably achieve given current market conditions. The Fed's recent pause on rate hikes but commitment to keeping rates higher for longer generates important discussion about economic fragility. The panelists speculate on which sectors or asset classes might experience stress if the economy deteriorates further. Credit markets, commercial real estate, and consumer spending receive particular scrutiny as potential pressure points. The episode concludes with a Science Corner segment discussing a breakthrough inverse-vaccine treatment for autoimmune diseases. This innovative approach, which differs fundamentally from traditional vaccines, could represent a paradigm shift in immunotherapy. The panelists discuss the commercial and healthcare implications of this scientific development. Throughout the discussion, the panel examines interconnections between monetary policy, venture capital, public markets, and economic health. The overarching theme concerns how the transition from easy money to restrictive monetary policy reshapes incentives and valuations across the investment landscape. The episode provides valuable perspective on how market participants are adapting to a fundamentally changed operating environment.